rac-1-cyclobutyl-2,2,2-trifluoroethanamine hydrochloride | 2055390-11-7

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: rac-1-cyclobutyl-2,2,2-trifluoroethanamine hydrochloride
• 英文别名: 1-cyclobutyl-2,2,2-trifluoroethanamine hydrochloride；1-Cyclobutyl-2,2,2-trifluoroethan-1-amine hydrochloride；1-cyclobutyl-2,2,2-trifluoroethanamine;hydrochloride
• CAS: 2055390-11-7
• 化学式: C₆H₁₀F₃N*ClH
• 分子量: 189.608
• InChiKey: HHUPGJBPRKSYMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  rac-1-cyclobutyl-2,2,2-trifluoroethanamine hydrochloride 、 (2-(二氟甲氧基)吡啶-4-基)甲胺 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 以10 %的产率得到1-(1-cyclobutyl-2,2,2-trifluoroethyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea
  参考文献：
  名称：

  NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS

  摘要：

  The invention provides new heteroaromatic compounds having the general formula (I'), or a solvate or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, and n are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

  公开号：

  WO2023091554A1

文献信息

• POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20180297994A1

  公开（公告）日：2018-10-18

  The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.

  本申请涉及肌动蛋白M2受体的阳性变构调节剂，特别是新型的7-取代的1-芳基萘啶-3-羧酰胺，以及其制备方法，单独或组合使用于治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病和/或肾脏疾病。
• Positive allosteric modulators of muscarinic M2 receptor
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US10435403B2

  公开（公告）日：2019-10-08

  The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.

  本申请涉及毒蕈碱 M2 受体的正性异位调节剂，特别是新型 7-取代 1-芳基萘啶-3-羧酰胺，涉及其制备工艺，涉及其单独或组合用于治疗和/或预防疾病，以及涉及其用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病和/或肾脏疾病。